| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatology | 57 | 2022 | 75 | 24.220 |
Why?
|
| Skin Neoplasms | 80 | 2022 | 375 | 21.060 |
Why?
|
| Skin Diseases | 39 | 2021 | 122 | 12.620 |
Why?
|
| Alopecia | 23 | 2021 | 45 | 8.350 |
Why?
|
| Melanoma | 31 | 2022 | 335 | 8.270 |
Why?
|
| Skin | 36 | 2022 | 451 | 7.270 |
Why?
|
| Humans | 488 | 2023 | 68618 | 7.210 |
Why?
|
| Insect Bites and Stings | 24 | 2022 | 47 | 6.950 |
Why?
|
| Bites and Stings | 21 | 2022 | 34 | 6.430 |
Why?
|
| Publishing | 11 | 2021 | 89 | 5.780 |
Why?
|
| Tick-Borne Diseases | 16 | 2018 | 20 | 5.530 |
Why?
|
| Periodicals as Topic | 14 | 2022 | 158 | 5.440 |
Why?
|
| Dermatitis | 13 | 2021 | 28 | 4.870 |
Why?
|
| Diagnosis, Differential | 72 | 2022 | 1140 | 4.790 |
Why?
|
| Psoriasis | 10 | 2022 | 46 | 4.190 |
Why?
|
| Hair Follicle | 12 | 2021 | 37 | 4.150 |
Why?
|
| Siphonaptera | 11 | 2020 | 11 | 3.960 |
Why?
|
| Lice Infestations | 13 | 2020 | 14 | 3.600 |
Why?
|
| Elastic Tissue | 9 | 2018 | 28 | 3.180 |
Why?
|
| Immunohistochemistry | 29 | 2019 | 1174 | 3.150 |
Why?
|
| Mycosis Fungoides | 8 | 2022 | 16 | 3.120 |
Why?
|
| Animals | 121 | 2022 | 20881 | 3.070 |
Why?
|
| Ixodes | 6 | 2020 | 6 | 2.840 |
Why?
|
| Scorpion Stings | 7 | 2020 | 8 | 2.770 |
Why?
|
| Lichen Planus | 11 | 2020 | 17 | 2.720 |
Why?
|
| Nevus, Pigmented | 8 | 2022 | 30 | 2.690 |
Why?
|
| Epidermis | 6 | 2018 | 42 | 2.680 |
Why?
|
| Skin Diseases, Infectious | 8 | 2018 | 16 | 2.650 |
Why?
|
| Histiocytoma, Benign Fibrous | 5 | 2019 | 10 | 2.560 |
Why?
|
| Insecticides | 9 | 2020 | 43 | 2.540 |
Why?
|
| Keratoacanthoma | 5 | 2020 | 8 | 2.510 |
Why?
|
| Male | 130 | 2022 | 37321 | 2.350 |
Why?
|
| Pediculus | 7 | 2020 | 8 | 2.320 |
Why?
|
| Tick Infestations | 5 | 2018 | 6 | 2.320 |
Why?
|
| Mite Infestations | 6 | 2017 | 7 | 2.200 |
Why?
|
| Scorpions | 7 | 2020 | 9 | 2.170 |
Why?
|
| Facial Dermatoses | 9 | 2016 | 14 | 2.120 |
Why?
|
| Medical Errors | 6 | 2020 | 80 | 2.120 |
Why?
|
| Anti-Bacterial Agents | 17 | 2021 | 1026 | 2.090 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2020 | 24 | 2.090 |
Why?
|
| Flea Infestations | 4 | 2019 | 4 | 2.060 |
Why?
|
| Methicillin Resistance | 9 | 2013 | 45 | 2.050 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2016 | 629 | 2.050 |
Why?
|
| Insect Vectors | 7 | 2020 | 9 | 2.040 |
Why?
|
| Nevus | 4 | 2021 | 17 | 2.030 |
Why?
|
| Hidradenitis Suppurativa | 3 | 2020 | 6 | 2.030 |
Why?
|
| Carcinoma, Basal Cell | 7 | 2016 | 40 | 2.000 |
Why?
|
| Research Design | 5 | 2017 | 729 | 2.000 |
Why?
|
| Staphylococcal Skin Infections | 10 | 2013 | 14 | 2.000 |
Why?
|
| Editorial Policies | 7 | 2021 | 32 | 1.970 |
Why?
|
| Female | 113 | 2022 | 38074 | 1.920 |
Why?
|
| Ectoparasitic Infestations | 8 | 2014 | 9 | 1.910 |
Why?
|
| Mites | 6 | 2017 | 6 | 1.900 |
Why?
|
| Syphilis | 3 | 2020 | 15 | 1.890 |
Why?
|
| S100 Proteins | 8 | 2015 | 42 | 1.890 |
Why?
|
| Staining and Labeling | 9 | 2019 | 144 | 1.880 |
Why?
|
| United States | 44 | 2021 | 7367 | 1.870 |
Why?
|
| Biopsy, Needle | 13 | 2018 | 191 | 1.830 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 4 | 2022 | 11 | 1.810 |
Why?
|
| Staphylococcus aureus | 7 | 2013 | 175 | 1.770 |
Why?
|
| Spider Bites | 7 | 2011 | 9 | 1.750 |
Why?
|
| Skin Diseases, Parasitic | 7 | 2014 | 8 | 1.740 |
Why?
|
| Coloring Agents | 5 | 2020 | 66 | 1.740 |
Why?
|
| Porokeratosis | 3 | 2022 | 4 | 1.720 |
Why?
|
| Carcinoma in Situ | 4 | 2017 | 47 | 1.700 |
Why?
|
| Melanocytes | 5 | 2015 | 23 | 1.670 |
Why?
|
| Biopsy | 17 | 2022 | 540 | 1.670 |
Why?
|
| Biomarkers, Tumor | 9 | 2016 | 508 | 1.650 |
Why?
|
| Precancerous Conditions | 5 | 2016 | 74 | 1.640 |
Why?
|
| Diagnostic Errors | 5 | 2019 | 100 | 1.630 |
Why?
|
| Arthropod Venoms | 3 | 2020 | 3 | 1.620 |
Why?
|
| Penile Diseases | 5 | 2018 | 6 | 1.590 |
Why?
|
| Peer Review, Research | 4 | 2022 | 21 | 1.580 |
Why?
|
| Data Interpretation, Statistical | 3 | 2017 | 329 | 1.570 |
Why?
|
| Hair Diseases | 7 | 2016 | 11 | 1.540 |
Why?
|
| Quality Assurance, Health Care | 5 | 2011 | 177 | 1.540 |
Why?
|
| Societies, Medical | 11 | 2021 | 403 | 1.530 |
Why?
|
| Microscopy, Fluorescence | 5 | 2018 | 261 | 1.520 |
Why?
|
| Retrospective Studies | 28 | 2022 | 7277 | 1.520 |
Why?
|
| Middle Aged | 67 | 2022 | 21147 | 1.510 |
Why?
|
| Cultural Diversity | 2 | 2022 | 67 | 1.500 |
Why?
|
| Skin Diseases, Bacterial | 7 | 2009 | 17 | 1.500 |
Why?
|
| Scabies | 5 | 2017 | 7 | 1.490 |
Why?
|
| Scalp | 10 | 2020 | 47 | 1.490 |
Why?
|
| Lichenoid Eruptions | 3 | 2017 | 3 | 1.470 |
Why?
|
| Laboratories | 4 | 2017 | 44 | 1.470 |
Why?
|
| Alopecia Areata | 4 | 2020 | 17 | 1.440 |
Why?
|
| Polyarteritis Nodosa | 3 | 2022 | 9 | 1.440 |
Why?
|
| Pathology, Clinical | 6 | 2021 | 16 | 1.430 |
Why?
|
| Hydroa Vacciniforme | 2 | 2020 | 4 | 1.420 |
Why?
|
| Adult | 66 | 2022 | 21403 | 1.410 |
Why?
|
| Hyperpigmentation | 4 | 2017 | 7 | 1.410 |
Why?
|
| Coronavirus | 2 | 2020 | 16 | 1.400 |
Why?
|
| Rocky Mountain Spotted Fever | 5 | 2020 | 8 | 1.390 |
Why?
|
| Laser Therapy | 4 | 2018 | 54 | 1.390 |
Why?
|
| Acanthoma | 3 | 2014 | 3 | 1.380 |
Why?
|
| Dermatofibrosarcoma | 5 | 2019 | 8 | 1.380 |
Why?
|
| Arthropods | 4 | 2019 | 8 | 1.360 |
Why?
|
| Dermacentor | 4 | 2018 | 4 | 1.360 |
Why?
|
| Dermis | 3 | 2015 | 29 | 1.360 |
Why?
|
| Staphylococcal Infections | 6 | 2009 | 156 | 1.360 |
Why?
|
| Dysplastic Nevus Syndrome | 3 | 2014 | 6 | 1.350 |
Why?
|
| Biological Products | 2 | 2020 | 78 | 1.340 |
Why?
|
| Dermatitis, Contact | 5 | 2022 | 14 | 1.330 |
Why?
|
| Benzophenoneidum | 2 | 2020 | 2 | 1.320 |
Why?
|
| Pemphigoid, Bullous | 4 | 2017 | 13 | 1.320 |
Why?
|
| Rhodamines | 2 | 2020 | 27 | 1.300 |
Why?
|
| Penis | 2 | 2020 | 25 | 1.300 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 143 | 1.290 |
Why?
|
| Scalp Dermatoses | 8 | 2019 | 13 | 1.280 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 154 | 1.280 |
Why?
|
| Dermatitis, Phototoxic | 3 | 2021 | 4 | 1.240 |
Why?
|
| Scorpion Venoms | 3 | 2019 | 4 | 1.240 |
Why?
|
| Bowen's Disease | 3 | 2017 | 6 | 1.220 |
Why?
|
| Pandemics | 3 | 2020 | 352 | 1.220 |
Why?
|
| Fluorescent Dyes | 2 | 2020 | 191 | 1.220 |
Why?
|
| Pyrimidines | 4 | 2022 | 178 | 1.210 |
Why?
|
| Sensitivity and Specificity | 14 | 2020 | 1753 | 1.210 |
Why?
|
| Tinea | 5 | 2016 | 6 | 1.200 |
Why?
|
| Nail Diseases | 4 | 2018 | 13 | 1.200 |
Why?
|
| Exanthema | 2 | 2023 | 30 | 1.200 |
Why?
|
| Writing | 2 | 2017 | 29 | 1.190 |
Why?
|
| Sarcoptes scabiei | 3 | 2017 | 5 | 1.180 |
Why?
|
| Mycoses | 5 | 2010 | 60 | 1.160 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2017 | 46 | 1.160 |
Why?
|
| Rickettsia | 3 | 2020 | 3 | 1.160 |
Why?
|
| Sweat Gland Neoplasms | 5 | 2016 | 16 | 1.140 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2018 | 157 | 1.130 |
Why?
|
| Hypersensitivity | 3 | 2022 | 52 | 1.120 |
Why?
|
| Hand Dermatoses | 6 | 2016 | 10 | 1.120 |
Why?
|
| Xenopsylla | 2 | 2020 | 2 | 1.120 |
Why?
|
| Aged | 44 | 2020 | 14862 | 1.110 |
Why?
|
| Bias | 4 | 2019 | 148 | 1.110 |
Why?
|
| Dermatomyositis | 3 | 2022 | 31 | 1.100 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 772 | 1.090 |
Why?
|
| Ixodidae | 3 | 2017 | 7 | 1.080 |
Why?
|
| Neoplasm Proteins | 4 | 2016 | 307 | 1.080 |
Why?
|
| Plants, Medicinal | 2 | 2022 | 43 | 1.080 |
Why?
|
| Disease Vectors | 4 | 2020 | 8 | 1.080 |
Why?
|
| Child | 25 | 2021 | 6405 | 1.060 |
Why?
|
| Biomedical Research | 3 | 2017 | 310 | 1.050 |
Why?
|
| Dermatologic Agents | 4 | 2020 | 32 | 1.040 |
Why?
|
| Cicatrix | 6 | 2017 | 60 | 1.030 |
Why?
|
| Plague | 5 | 2020 | 9 | 1.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2013 | 92 | 1.020 |
Why?
|
| Mycobacterium Infections | 2 | 2020 | 13 | 1.010 |
Why?
|
| Fish Venoms | 3 | 2019 | 3 | 1.010 |
Why?
|
| Porifera | 2 | 2021 | 58 | 1.010 |
Why?
|
| Tissue Fixation | 2 | 2015 | 58 | 1.000 |
Why?
|
| Physicians | 3 | 2019 | 324 | 1.000 |
Why?
|
| Spider Venoms | 4 | 2011 | 5 | 0.970 |
Why?
|
| Leiomyosarcoma | 2 | 2015 | 17 | 0.960 |
Why?
|
| Risk Assessment | 15 | 2021 | 2007 | 0.960 |
Why?
|
| Insect Control | 5 | 2019 | 16 | 0.950 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 3 | 2022 | 10 | 0.950 |
Why?
|
| Eczema | 2 | 2022 | 10 | 0.950 |
Why?
|
| Community-Acquired Infections | 4 | 2008 | 46 | 0.950 |
Why?
|
| Leiomyoma | 2 | 2015 | 28 | 0.950 |
Why?
|
| Coleoptera | 2 | 2019 | 8 | 0.950 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2016 | 7 | 0.940 |
Why?
|
| Fluorescent Antibody Technique, Direct | 5 | 2016 | 21 | 0.940 |
Why?
|
| Microscopy, Polarization | 4 | 2016 | 7 | 0.940 |
Why?
|
| Hyperhidrosis | 2 | 2021 | 4 | 0.940 |
Why?
|
| Purpura | 3 | 2021 | 7 | 0.930 |
Why?
|
| Piperidines | 3 | 2022 | 123 | 0.930 |
Why?
|
| Quality Improvement | 3 | 2017 | 413 | 0.930 |
Why?
|
| Dermatitis, Irritant | 2 | 2023 | 2 | 0.910 |
Why?
|
| Antiparasitic Agents | 4 | 2017 | 12 | 0.900 |
Why?
|
| Authorship | 3 | 2017 | 18 | 0.900 |
Why?
|
| Patient Safety | 3 | 2020 | 202 | 0.900 |
Why?
|
| Dermatologists | 2 | 2020 | 5 | 0.900 |
Why?
|
| Immunologic Factors | 2 | 2022 | 87 | 0.900 |
Why?
|
| Ultraviolet Rays | 2 | 2021 | 130 | 0.890 |
Why?
|
| American Medical Association | 2 | 2013 | 21 | 0.890 |
Why?
|
| Methotrexate | 2 | 2021 | 91 | 0.890 |
Why?
|
| Keratosis, Actinic | 2 | 2013 | 8 | 0.890 |
Why?
|
| Skin Diseases, Vesiculobullous | 6 | 2021 | 14 | 0.890 |
Why?
|
| Culicidae | 2 | 2022 | 12 | 0.880 |
Why?
|
| Narcissus | 1 | 2023 | 1 | 0.870 |
Why?
|
| Trombiculiasis | 2 | 2017 | 2 | 0.870 |
Why?
|
| Trombiculidae | 2 | 2017 | 2 | 0.870 |
Why?
|
| Pemphigus, Benign Familial | 3 | 2018 | 4 | 0.860 |
Why?
|
| Quality Control | 4 | 2019 | 81 | 0.860 |
Why?
|
| Fluorouracil | 2 | 2020 | 130 | 0.850 |
Why?
|
| Adenocarcinoma | 3 | 2016 | 475 | 0.850 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 230 | 0.850 |
Why?
|
| Inflammation | 5 | 2021 | 1030 | 0.840 |
Why?
|
| Information Dissemination | 2 | 2020 | 113 | 0.840 |
Why?
|
| Ginkgo biloba | 1 | 2022 | 4 | 0.840 |
Why?
|
| Shoulder | 2 | 2019 | 37 | 0.840 |
Why?
|
| Manuscripts as Topic | 2 | 2019 | 3 | 0.840 |
Why?
|
| Hair | 7 | 2020 | 46 | 0.830 |
Why?
|
| Raynaud Disease | 2 | 2021 | 24 | 0.830 |
Why?
|
| Latent Tuberculosis | 1 | 2022 | 13 | 0.820 |
Why?
|
| Scyphozoa | 1 | 2022 | 1 | 0.810 |
Why?
|
| Lyme Disease | 4 | 2018 | 17 | 0.810 |
Why?
|
| Faculty, Medical | 2 | 2014 | 110 | 0.810 |
Why?
|
| Spironolactone | 1 | 2022 | 13 | 0.810 |
Why?
|
| Herpes Zoster | 2 | 2019 | 43 | 0.810 |
Why?
|
| Purpura Fulminans | 1 | 2021 | 2 | 0.800 |
Why?
|
| Mycobacterium | 2 | 2020 | 12 | 0.800 |
Why?
|
| Splenic Diseases | 1 | 2021 | 10 | 0.800 |
Why?
|
| Sanguinaria | 1 | 2021 | 1 | 0.800 |
Why?
|
| Trust | 1 | 2022 | 75 | 0.800 |
Why?
|
| Drug Users | 1 | 2021 | 10 | 0.800 |
Why?
|
| Pityriasis Rosea | 2 | 2019 | 3 | 0.790 |
Why?
|
| Hutchinson's Melanotic Freckle | 3 | 2016 | 5 | 0.790 |
Why?
|
| Ivermectin | 5 | 2017 | 12 | 0.780 |
Why?
|
| Cytoplasm | 3 | 2017 | 155 | 0.780 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2021 | 30 | 0.780 |
Why?
|
| Granuloma | 3 | 2014 | 21 | 0.780 |
Why?
|
| Psychodidae | 2 | 2018 | 2 | 0.780 |
Why?
|
| Potassium | 1 | 2022 | 168 | 0.780 |
Why?
|
| Ficusin | 1 | 2021 | 1 | 0.780 |
Why?
|
| Photosensitivity Disorders | 1 | 2021 | 7 | 0.780 |
Why?
|
| Furocoumarins | 1 | 2021 | 9 | 0.770 |
Why?
|
| Babesiosis | 2 | 2018 | 9 | 0.770 |
Why?
|
| Vitiligo | 1 | 2021 | 12 | 0.770 |
Why?
|
| Tick Bites | 2 | 2018 | 2 | 0.770 |
Why?
|
| Pathology | 3 | 2018 | 17 | 0.770 |
Why?
|
| Cell Nucleus | 4 | 2017 | 305 | 0.770 |
Why?
|
| Drug Eruptions | 3 | 2017 | 16 | 0.770 |
Why?
|
| Plant Extracts | 4 | 2022 | 122 | 0.770 |
Why?
|
| Hepatitis B | 2 | 2020 | 42 | 0.760 |
Why?
|
| Anti-Infective Agents | 3 | 2020 | 166 | 0.760 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 4848 | 0.750 |
Why?
|
| Zinc Compounds | 1 | 2020 | 9 | 0.750 |
Why?
|
| Gelatin | 1 | 2020 | 14 | 0.750 |
Why?
|
| Compression Bandages | 1 | 2020 | 6 | 0.750 |
Why?
|
| Nose Neoplasms | 2 | 2019 | 25 | 0.740 |
Why?
|
| Photochemotherapy | 2 | 2022 | 59 | 0.740 |
Why?
|
| Glycerol | 1 | 2020 | 26 | 0.740 |
Why?
|
| Yersinia pestis | 1 | 2020 | 6 | 0.740 |
Why?
|
| Scoliosis | 1 | 2021 | 42 | 0.740 |
Why?
|
| Conflict of Interest | 2 | 2020 | 48 | 0.740 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2020 | 8 | 0.730 |
Why?
|
| Head and Neck Neoplasms | 3 | 2016 | 561 | 0.730 |
Why?
|
| Lymphoma, T-Cell | 2 | 2019 | 19 | 0.730 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 23 | 0.730 |
Why?
|
| Hepatitis B, Chronic | 1 | 2020 | 19 | 0.730 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2020 | 1 | 0.730 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2020 | 6 | 0.720 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2020 | 12 | 0.720 |
Why?
|
| Crowdsourcing | 1 | 2020 | 8 | 0.720 |
Why?
|
| Evidence-Based Medicine | 5 | 2021 | 438 | 0.720 |
Why?
|
| Pemphigus | 2 | 2016 | 12 | 0.710 |
Why?
|
| Eosine Yellowish-(YS) | 2 | 2018 | 6 | 0.710 |
Why?
|
| Hematoxylin | 2 | 2018 | 8 | 0.710 |
Why?
|
| Gout | 1 | 2020 | 9 | 0.710 |
Why?
|
| Climate Change | 1 | 2020 | 17 | 0.710 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 2 | 2018 | 7 | 0.710 |
Why?
|
| Skin Abnormalities | 1 | 2020 | 11 | 0.710 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2020 | 37 | 0.710 |
Why?
|
| Wasp Venoms | 1 | 2020 | 8 | 0.710 |
Why?
|
| Hymenoptera | 1 | 2020 | 4 | 0.710 |
Why?
|
| Treatment Outcome | 15 | 2022 | 7029 | 0.710 |
Why?
|
| Ticks | 6 | 2011 | 13 | 0.700 |
Why?
|
| Blood Loss, Surgical | 1 | 2020 | 79 | 0.700 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 151 | 0.700 |
Why?
|
| Bandages, Hydrocolloid | 1 | 2019 | 3 | 0.700 |
Why?
|
| Sugars | 1 | 2019 | 7 | 0.690 |
Why?
|
| Ctenocephalides | 1 | 2019 | 1 | 0.690 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2019 | 5 | 0.690 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2019 | 4 | 0.690 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 131 | 0.690 |
Why?
|
| Pityriasis Lichenoides | 1 | 2019 | 1 | 0.690 |
Why?
|
| Hemangioma | 3 | 2018 | 51 | 0.680 |
Why?
|
| Dermatitis, Allergic Contact | 3 | 2011 | 12 | 0.680 |
Why?
|
| Incidence | 10 | 2015 | 1603 | 0.680 |
Why?
|
| Social Networking | 1 | 2019 | 14 | 0.680 |
Why?
|
| Prognosis | 10 | 2018 | 2093 | 0.680 |
Why?
|
| Photomicrography | 2 | 2018 | 14 | 0.670 |
Why?
|
| Virtual Reality | 1 | 2019 | 13 | 0.670 |
Why?
|
| Bimatoprost | 1 | 2019 | 1 | 0.670 |
Why?
|
| Hypertrichosis | 1 | 2019 | 1 | 0.670 |
Why?
|
| Thallium | 1 | 2019 | 3 | 0.670 |
Why?
|
| Papillomavirus Infections | 2 | 2013 | 194 | 0.670 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2009 | 98 | 0.670 |
Why?
|
| Air Pollutants, Occupational | 1 | 2019 | 7 | 0.670 |
Why?
|
| Benzoquinones | 1 | 2019 | 13 | 0.670 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2019 | 33 | 0.670 |
Why?
|
| Odorants | 1 | 2019 | 52 | 0.670 |
Why?
|
| Burns, Chemical | 1 | 2019 | 7 | 0.670 |
Why?
|
| Warfare | 3 | 2004 | 58 | 0.670 |
Why?
|
| Professionalism | 1 | 2019 | 28 | 0.670 |
Why?
|
| Military Personnel | 3 | 2015 | 221 | 0.660 |
Why?
|
| Lymphoma | 1 | 2019 | 116 | 0.660 |
Why?
|
| Ophthalmic Solutions | 1 | 2019 | 39 | 0.660 |
Why?
|
| Sweat Glands | 2 | 2016 | 10 | 0.660 |
Why?
|
| Likelihood Functions | 1 | 2019 | 106 | 0.660 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 234 | 0.660 |
Why?
|
| Truth Disclosure | 1 | 2019 | 48 | 0.660 |
Why?
|
| Immunotherapy | 2 | 2022 | 215 | 0.650 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 2 | 2010 | 4 | 0.650 |
Why?
|
| Communicable Disease Control | 2 | 2017 | 26 | 0.650 |
Why?
|
| Acne Vulgaris | 3 | 2016 | 11 | 0.650 |
Why?
|
| Clinical Competence | 5 | 2017 | 657 | 0.650 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2018 | 12 | 0.650 |
Why?
|
| Introduced Species | 1 | 2018 | 7 | 0.640 |
Why?
|
| Breast Neoplasms | 4 | 2018 | 1536 | 0.640 |
Why?
|
| Statistics as Topic | 1 | 2019 | 219 | 0.640 |
Why?
|
| Safety Management | 2 | 2009 | 73 | 0.640 |
Why?
|
| Perciformes | 1 | 2018 | 8 | 0.640 |
Why?
|
| Cholinergic Antagonists | 1 | 2018 | 17 | 0.640 |
Why?
|
| Hypopigmentation | 2 | 2015 | 12 | 0.630 |
Why?
|
| Moths | 4 | 2020 | 14 | 0.630 |
Why?
|
| Mycobacterium leprae | 2 | 2017 | 2 | 0.630 |
Why?
|
| Phthirus | 2 | 2008 | 2 | 0.630 |
Why?
|
| Communicable Diseases, Emerging | 3 | 2010 | 13 | 0.630 |
Why?
|
| Education, Medical | 1 | 2020 | 147 | 0.630 |
Why?
|
| Dermatomycoses | 3 | 2014 | 17 | 0.630 |
Why?
|
| Allergens | 3 | 2022 | 54 | 0.630 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 109 | 0.630 |
Why?
|
| Erythrocytes | 1 | 2018 | 137 | 0.620 |
Why?
|
| Anus Diseases | 1 | 2018 | 5 | 0.620 |
Why?
|
| Social Media | 1 | 2019 | 59 | 0.620 |
Why?
|
| Leishmaniasis | 1 | 2018 | 4 | 0.620 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2018 | 3 | 0.620 |
Why?
|
| Decision Making | 2 | 2019 | 410 | 0.620 |
Why?
|
| Taxoids | 1 | 2018 | 41 | 0.610 |
Why?
|
| Research | 1 | 2019 | 214 | 0.610 |
Why?
|
| Bedbugs | 2 | 2012 | 6 | 0.610 |
Why?
|
| Crohn Disease | 1 | 2018 | 38 | 0.610 |
Why?
|
| PubMed | 1 | 2017 | 21 | 0.610 |
Why?
|
| Peer Review | 1 | 2017 | 16 | 0.610 |
Why?
|
| Information Seeking Behavior | 1 | 2017 | 10 | 0.600 |
Why?
|
| Condylomata Acuminata | 2 | 2018 | 12 | 0.600 |
Why?
|
| Virus Diseases | 2 | 2009 | 31 | 0.590 |
Why?
|
| Sample Size | 1 | 2017 | 79 | 0.590 |
Why?
|
| Paget Disease, Extramammary | 1 | 2017 | 5 | 0.590 |
Why?
|
| Paget's Disease, Mammary | 1 | 2017 | 4 | 0.590 |
Why?
|
| Perilipins | 1 | 2017 | 1 | 0.590 |
Why?
|
| Arthropod Vectors | 2 | 2009 | 3 | 0.590 |
Why?
|
| Research Report | 1 | 2017 | 35 | 0.590 |
Why?
|
| Mass Screening | 2 | 2022 | 843 | 0.590 |
Why?
|
| Drug Combinations | 5 | 2020 | 304 | 0.590 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 184 | 0.580 |
Why?
|
| Anti-Infective Agents, Local | 3 | 2007 | 40 | 0.580 |
Why?
|
| Pain | 2 | 2020 | 472 | 0.580 |
Why?
|
| Ants | 2 | 2015 | 21 | 0.580 |
Why?
|
| Gadolinium | 1 | 2018 | 88 | 0.580 |
Why?
|
| Ointments | 4 | 2022 | 15 | 0.580 |
Why?
|
| Cnidarian Venoms | 2 | 2007 | 4 | 0.580 |
Why?
|
| Antivenins | 4 | 2020 | 12 | 0.580 |
Why?
|
| Naltrexone | 1 | 2018 | 195 | 0.580 |
Why?
|
| Erythema | 1 | 2017 | 18 | 0.580 |
Why?
|
| Cats | 6 | 2019 | 292 | 0.570 |
Why?
|
| Pathologists | 1 | 2017 | 10 | 0.570 |
Why?
|
| Papillomaviridae | 3 | 2013 | 104 | 0.570 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 492 | 0.570 |
Why?
|
| Plants, Toxic | 3 | 2021 | 33 | 0.570 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2016 | 2 | 0.570 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 284 | 0.560 |
Why?
|
| Angiomatosis, Bacillary | 2 | 2014 | 3 | 0.560 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2017 | 75 | 0.560 |
Why?
|
| Lentigo | 2 | 2014 | 4 | 0.560 |
Why?
|
| Dementia | 1 | 2018 | 158 | 0.560 |
Why?
|
| Keratosis | 2 | 2014 | 17 | 0.560 |
Why?
|
| Antigens, CD | 3 | 2014 | 230 | 0.550 |
Why?
|
| Cysts | 2 | 2010 | 70 | 0.550 |
Why?
|
| Urogenital Neoplasms | 1 | 2016 | 9 | 0.550 |
Why?
|
| Academies and Institutes | 3 | 2020 | 31 | 0.550 |
Why?
|
| Triatominae | 2 | 2011 | 2 | 0.550 |
Why?
|
| Sebaceous Glands | 1 | 2016 | 8 | 0.550 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 66 | 0.550 |
Why?
|
| GATA3 Transcription Factor | 1 | 2016 | 6 | 0.550 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 1070 | 0.540 |
Why?
|
| T-Box Domain Proteins | 1 | 2016 | 29 | 0.540 |
Why?
|
| Eccrine Glands | 1 | 2016 | 3 | 0.540 |
Why?
|
| Fibrillar Collagens | 1 | 2016 | 49 | 0.540 |
Why?
|
| Phosphoric Diester Hydrolases | 2 | 2007 | 22 | 0.540 |
Why?
|
| Bacterial Infections | 2 | 2009 | 163 | 0.530 |
Why?
|
| Ki-67 Antigen | 2 | 2013 | 29 | 0.530 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 334 | 0.530 |
Why?
|
| Syphilis, Cutaneous | 1 | 2015 | 2 | 0.530 |
Why?
|
| Anus Neoplasms | 1 | 2016 | 37 | 0.520 |
Why?
|
| Angiomyoma | 1 | 2015 | 1 | 0.520 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2015 | 1 | 0.520 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 2015 | 2 | 0.520 |
Why?
|
| Tissue Preservation | 1 | 2015 | 44 | 0.520 |
Why?
|
| Nails | 2 | 2006 | 15 | 0.510 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 172 | 0.510 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 127 | 0.510 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 161 | 0.510 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2015 | 4 | 0.510 |
Why?
|
| Permethrin | 5 | 2009 | 11 | 0.510 |
Why?
|
| Cognition | 1 | 2019 | 513 | 0.510 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 2015 | 38 | 0.510 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2015 | 25 | 0.510 |
Why?
|
| Rickettsia Infections | 3 | 2017 | 3 | 0.500 |
Why?
|
| Eyelid Diseases | 1 | 2014 | 7 | 0.500 |
Why?
|
| Foot Dermatoses | 3 | 2013 | 12 | 0.500 |
Why?
|
| Health Care Reform | 3 | 2010 | 62 | 0.500 |
Why?
|
| Xanthomatosis | 1 | 2014 | 7 | 0.500 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 498 | 0.500 |
Why?
|
| Adenylyl Cyclases | 1 | 2014 | 94 | 0.490 |
Why?
|
| Smartphone | 1 | 2015 | 69 | 0.490 |
Why?
|
| Health Priorities | 1 | 2014 | 23 | 0.490 |
Why?
|
| Gene Expression | 1 | 2017 | 770 | 0.480 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2013 | 92 | 0.480 |
Why?
|
| Antibodies | 1 | 2015 | 241 | 0.480 |
Why?
|
| Colchicine | 3 | 2005 | 48 | 0.480 |
Why?
|
| Betacoronavirus | 3 | 2020 | 116 | 0.480 |
Why?
|
| Internship and Residency | 1 | 2020 | 596 | 0.470 |
Why?
|
| Bartonella | 1 | 2014 | 2 | 0.470 |
Why?
|
| Bartonella Infections | 1 | 2014 | 2 | 0.470 |
Why?
|
| Nose Diseases | 2 | 2007 | 8 | 0.470 |
Why?
|
| Penile Neoplasms | 4 | 2010 | 12 | 0.470 |
Why?
|
| Lip | 1 | 2014 | 12 | 0.470 |
Why?
|
| Pruritus | 5 | 2018 | 35 | 0.470 |
Why?
|
| Patient Care | 1 | 2014 | 61 | 0.470 |
Why?
|
| Sphingolipids | 1 | 2017 | 337 | 0.470 |
Why?
|
| Nevus, Sebaceous of Jadassohn | 1 | 2013 | 2 | 0.460 |
Why?
|
| Folliculitis | 2 | 2011 | 2 | 0.450 |
Why?
|
| Genital Neoplasms, Male | 1 | 2013 | 2 | 0.450 |
Why?
|
| Communicable Diseases | 2 | 2004 | 50 | 0.450 |
Why?
|
| Hygiene | 2 | 2020 | 11 | 0.450 |
Why?
|
| Sweet Syndrome | 2 | 2003 | 2 | 0.440 |
Why?
|
| Thrombophlebitis | 1 | 2013 | 47 | 0.440 |
Why?
|
| Reimbursement Mechanisms | 2 | 2013 | 37 | 0.440 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 51 | 0.440 |
Why?
|
| Genital Neoplasms, Female | 1 | 2013 | 38 | 0.440 |
Why?
|
| Arthrodermataceae | 1 | 2013 | 4 | 0.440 |
Why?
|
| Antifungal Agents | 4 | 2010 | 108 | 0.440 |
Why?
|
| Onychomycosis | 1 | 2013 | 6 | 0.440 |
Why?
|
| Arachnid Vectors | 3 | 2018 | 5 | 0.440 |
Why?
|
| Dogs | 5 | 2019 | 490 | 0.440 |
Why?
|
| Severity of Illness Index | 10 | 2016 | 1851 | 0.430 |
Why?
|
| Environmental Exposure | 1 | 2015 | 269 | 0.430 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 199 | 0.430 |
Why?
|
| Carrier State | 3 | 2008 | 39 | 0.430 |
Why?
|
| Sunlight | 2 | 2011 | 59 | 0.430 |
Why?
|
| Chagas Disease | 2 | 2011 | 8 | 0.420 |
Why?
|
| Sezary Syndrome | 1 | 2012 | 3 | 0.420 |
Why?
|
| Ehrlichiosis | 4 | 2018 | 15 | 0.420 |
Why?
|
| Collagen | 1 | 2016 | 636 | 0.420 |
Why?
|
| Cantharidin | 2 | 2019 | 5 | 0.420 |
Why?
|
| Dermatitis, Atopic | 2 | 2021 | 17 | 0.420 |
Why?
|
| Carcinogenesis | 1 | 2013 | 124 | 0.420 |
Why?
|
| Ear, External | 2 | 2003 | 14 | 0.420 |
Why?
|
| Histones | 1 | 2013 | 111 | 0.410 |
Why?
|
| Syndrome | 5 | 2022 | 255 | 0.410 |
Why?
|
| Leg Dermatoses | 3 | 2010 | 6 | 0.410 |
Why?
|
| Quality Indicators, Health Care | 2 | 2010 | 136 | 0.410 |
Why?
|
| Ethics | 1 | 2012 | 17 | 0.410 |
Why?
|
| Fingers | 2 | 2022 | 39 | 0.410 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2012 | 16 | 0.410 |
Why?
|
| Bioethical Issues | 1 | 2012 | 10 | 0.410 |
Why?
|
| Administrative Personnel | 1 | 2012 | 22 | 0.400 |
Why?
|
| Insect Repellents | 2 | 2004 | 8 | 0.400 |
Why?
|
| Ear Diseases | 2 | 2003 | 37 | 0.400 |
Why?
|
| Stem Cells | 1 | 2013 | 248 | 0.400 |
Why?
|
| Histocytochemistry | 1 | 2012 | 149 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 756 | 0.400 |
Why?
|
| Malathion | 4 | 2007 | 4 | 0.400 |
Why?
|
| Hospitals, University | 1 | 2012 | 169 | 0.390 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2011 | 28 | 0.390 |
Why?
|
| Nipples | 1 | 2011 | 5 | 0.390 |
Why?
|
| Actinidia | 1 | 2011 | 1 | 0.390 |
Why?
|
| Eosinophils | 4 | 2012 | 60 | 0.390 |
Why?
|
| Young Adult | 8 | 2018 | 5717 | 0.390 |
Why?
|
| Insurance Coverage | 1 | 2012 | 99 | 0.390 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 848 | 0.390 |
Why?
|
| Choristoma | 1 | 2011 | 20 | 0.380 |
Why?
|
| Neurotoxins | 3 | 2020 | 30 | 0.380 |
Why?
|
| Food Hypersensitivity | 1 | 2011 | 20 | 0.380 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 1465 | 0.380 |
Why?
|
| Insecticide Resistance | 2 | 2017 | 3 | 0.380 |
Why?
|
| Chemistry, Clinical | 1 | 2010 | 6 | 0.380 |
Why?
|
| Rhipicephalus sanguineus | 1 | 2010 | 2 | 0.380 |
Why?
|
| Immunoglobulin E | 1 | 2011 | 91 | 0.380 |
Why?
|
| Nevus, Spindle Cell | 1 | 2010 | 1 | 0.370 |
Why?
|
| Veins | 2 | 2013 | 68 | 0.370 |
Why?
|
| Insurance, Health | 1 | 2012 | 201 | 0.370 |
Why?
|
| Human papillomavirus 16 | 1 | 2010 | 23 | 0.370 |
Why?
|
| Mitosis | 3 | 2016 | 76 | 0.370 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 149 | 0.370 |
Why?
|
| Dapsone | 4 | 2005 | 21 | 0.370 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 332 | 0.360 |
Why?
|
| Rabbits | 5 | 2017 | 509 | 0.360 |
Why?
|
| Foreign Bodies | 1 | 2011 | 58 | 0.360 |
Why?
|
| Lymphocytes | 1 | 2011 | 228 | 0.360 |
Why?
|
| Mucinoses | 1 | 2010 | 1 | 0.360 |
Why?
|
| Arteries | 2 | 2013 | 108 | 0.360 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2010 | 34 | 0.360 |
Why?
|
| Needs Assessment | 1 | 2011 | 186 | 0.360 |
Why?
|
| Breast | 1 | 2011 | 137 | 0.360 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1174 | 0.360 |
Why?
|
| Rare Diseases | 3 | 2019 | 41 | 0.350 |
Why?
|
| Triazoles | 1 | 2010 | 43 | 0.350 |
Why?
|
| Angelica | 1 | 2009 | 1 | 0.350 |
Why?
|
| Fibrosis | 3 | 2020 | 371 | 0.350 |
Why?
|
| Mohs Surgery | 5 | 2011 | 16 | 0.350 |
Why?
|
| Rhinosporidium | 1 | 2009 | 1 | 0.350 |
Why?
|
| Venous Insufficiency | 1 | 2010 | 27 | 0.350 |
Why?
|
| Dermoscopy | 2 | 2021 | 14 | 0.350 |
Why?
|
| Rhinosporidiosis | 1 | 2009 | 7 | 0.340 |
Why?
|
| Spiders | 3 | 2011 | 9 | 0.340 |
Why?
|
| Groin | 2 | 2020 | 11 | 0.340 |
Why?
|
| Drug Compounding | 2 | 2019 | 34 | 0.340 |
Why?
|
| Hedera | 1 | 2009 | 1 | 0.340 |
Why?
|
| Scleroderma, Localized | 2 | 2016 | 19 | 0.340 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2009 | 5 | 0.340 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 3259 | 0.340 |
Why?
|
| Amyloidosis | 2 | 2015 | 48 | 0.340 |
Why?
|
| Vulvar Lichen Sclerosus | 1 | 2009 | 2 | 0.340 |
Why?
|
| Zoonoses | 1 | 2009 | 12 | 0.340 |
Why?
|
| Fee-for-Service Plans | 1 | 2009 | 24 | 0.340 |
Why?
|
| Paracoccidioides | 1 | 2009 | 5 | 0.330 |
Why?
|
| Paracoccidioidomycosis | 1 | 2009 | 6 | 0.330 |
Why?
|
| Adolescent | 12 | 2019 | 8912 | 0.330 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2013 | 317 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 3 | 2022 | 504 | 0.330 |
Why?
|
| Tinea Versicolor | 2 | 2013 | 3 | 0.330 |
Why?
|
| Foot | 2 | 2019 | 66 | 0.320 |
Why?
|
| Certification | 1 | 2009 | 66 | 0.320 |
Why?
|
| Dermatitis, Occupational | 1 | 2008 | 5 | 0.320 |
Why?
|
| Photography | 2 | 2019 | 37 | 0.320 |
Why?
|
| Iron | 1 | 2010 | 197 | 0.320 |
Why?
|
| Staphylococcal Scalded Skin Syndrome | 2 | 2016 | 2 | 0.320 |
Why?
|
| Cross Infection | 2 | 2008 | 195 | 0.320 |
Why?
|
| Calcium Chloride | 1 | 2008 | 38 | 0.320 |
Why?
|
| Endemic Diseases | 2 | 2006 | 10 | 0.320 |
Why?
|
| Time Factors | 7 | 2018 | 4655 | 0.320 |
Why?
|
| S100 Calcium Binding Protein A6 | 3 | 2015 | 3 | 0.320 |
Why?
|
| MART-1 Antigen | 4 | 2011 | 10 | 0.320 |
Why?
|
| Complementary Therapies | 2 | 2005 | 43 | 0.320 |
Why?
|
| Mandatory Reporting | 1 | 2008 | 20 | 0.310 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2009 | 37 | 0.310 |
Why?
|
| Leg | 3 | 2019 | 191 | 0.310 |
Why?
|
| Bottle-Nosed Dolphin | 1 | 2009 | 86 | 0.310 |
Why?
|
| Journal Impact Factor | 2 | 2018 | 12 | 0.310 |
Why?
|
| Education, Medical, Continuing | 4 | 2016 | 136 | 0.310 |
Why?
|
| Impetigo | 2 | 2021 | 2 | 0.310 |
Why?
|
| POEMS Syndrome | 1 | 2007 | 2 | 0.310 |
Why?
|
| Soft Tissue Infections | 2 | 2007 | 19 | 0.310 |
Why?
|
| Stevens-Johnson Syndrome | 2 | 2016 | 11 | 0.300 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2004 | 4 | 0.300 |
Why?
|
| Hydrozoa | 1 | 2007 | 1 | 0.300 |
Why?
|
| Breast Neoplasms, Male | 1 | 2007 | 12 | 0.300 |
Why?
|
| Larva | 5 | 2021 | 39 | 0.300 |
Why?
|
| Publications | 2 | 2017 | 17 | 0.300 |
Why?
|
| Chronic Disease | 4 | 2019 | 1330 | 0.300 |
Why?
|
| Lepidoptera | 1 | 2007 | 4 | 0.300 |
Why?
|
| Fluorescence | 3 | 2017 | 104 | 0.300 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 1173 | 0.300 |
Why?
|
| Forecasting | 2 | 2019 | 277 | 0.300 |
Why?
|
| Neurilemmoma | 2 | 2001 | 26 | 0.290 |
Why?
|
| Quality of Health Care | 1 | 2010 | 322 | 0.290 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 62 | 0.290 |
Why?
|
| Emergency Treatment | 1 | 2007 | 52 | 0.290 |
Why?
|
| Sepsis | 1 | 2010 | 233 | 0.290 |
Why?
|
| Serine Endopeptidases | 1 | 2007 | 50 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 369 | 0.280 |
Why?
|
| Microsporum | 1 | 2006 | 1 | 0.280 |
Why?
|
| Mycetoma | 1 | 2006 | 3 | 0.280 |
Why?
|
| Acrospiroma | 2 | 2016 | 2 | 0.280 |
Why?
|
| Administration, Topical | 5 | 2009 | 111 | 0.280 |
Why?
|
| Nasal Mucosa | 1 | 2007 | 68 | 0.280 |
Why?
|
| Sea Anemones | 1 | 2006 | 1 | 0.280 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2006 | 6 | 0.280 |
Why?
|
| Hand Deformities, Congenital | 1 | 2006 | 2 | 0.280 |
Why?
|
| Scrub Typhus | 1 | 2006 | 2 | 0.280 |
Why?
|
| Melanosis | 2 | 2003 | 4 | 0.280 |
Why?
|
| Polydactyly | 1 | 2006 | 2 | 0.280 |
Why?
|
| Psoroptidae | 1 | 2006 | 1 | 0.280 |
Why?
|
| Sarcoidosis | 1 | 2007 | 77 | 0.270 |
Why?
|
| Fishes, Poisonous | 1 | 2006 | 2 | 0.270 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2016 | 31 | 0.270 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2006 | 60 | 0.270 |
Why?
|
| Blood Coagulation | 1 | 2007 | 123 | 0.270 |
Why?
|
| Skin Ulcer | 3 | 2019 | 19 | 0.270 |
Why?
|
| Tularemia | 2 | 2018 | 4 | 0.270 |
Why?
|
| Trichuris | 1 | 2006 | 2 | 0.270 |
Why?
|
| Fishes | 1 | 2006 | 77 | 0.270 |
Why?
|
| Trichuriasis | 1 | 2006 | 2 | 0.270 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2004 | 52 | 0.270 |
Why?
|
| Health Policy | 1 | 2008 | 221 | 0.270 |
Why?
|
| Prevalence | 4 | 2017 | 1619 | 0.270 |
Why?
|
| Helminths | 1 | 2006 | 2 | 0.270 |
Why?
|
| Antibodies, Helminth | 1 | 2006 | 2 | 0.270 |
Why?
|
| Ambulatory Care | 1 | 2008 | 340 | 0.270 |
Why?
|
| Helminthiasis | 1 | 2006 | 2 | 0.270 |
Why?
|
| Pyrethrins | 3 | 2017 | 6 | 0.270 |
Why?
|
| Hemangioendothelioma | 2 | 1998 | 2 | 0.270 |
Why?
|
| Tunica Intima | 1 | 2006 | 59 | 0.270 |
Why?
|
| Lymphangiectasis | 1 | 2005 | 1 | 0.270 |
Why?
|
| Microtomy | 1 | 2005 | 11 | 0.260 |
Why?
|
| Port-Wine Stain | 2 | 2013 | 7 | 0.260 |
Why?
|
| Sea Urchins | 1 | 2005 | 6 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 511 | 0.260 |
Why?
|
| Plants | 2 | 2023 | 26 | 0.260 |
Why?
|
| Dog Diseases | 2 | 2003 | 45 | 0.260 |
Why?
|
| Diphenhydramine | 1 | 2005 | 13 | 0.260 |
Why?
|
| Triamcinolone | 1 | 2005 | 11 | 0.250 |
Why?
|
| Phytotherapy | 1 | 2005 | 53 | 0.250 |
Why?
|
| Gentian Violet | 1 | 2005 | 6 | 0.250 |
Why?
|
| Tongue Neoplasms | 1 | 2005 | 29 | 0.250 |
Why?
|
| Ant Venoms | 1 | 2005 | 8 | 0.250 |
Why?
|
| Periodic Acid-Schiff Reaction | 2 | 2016 | 6 | 0.250 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 149 | 0.250 |
Why?
|
| Anemia, Hemolytic | 1 | 2004 | 37 | 0.250 |
Why?
|
| Risk Factors | 5 | 2021 | 5731 | 0.250 |
Why?
|
| Schistosomiasis mansoni | 1 | 2004 | 1 | 0.240 |
Why?
|
| Schistosoma mansoni | 1 | 2004 | 4 | 0.240 |
Why?
|
| Schistosomiasis japonica | 1 | 2004 | 1 | 0.240 |
Why?
|
| Schistosoma japonicum | 1 | 2004 | 2 | 0.240 |
Why?
|
| Schistosoma | 1 | 2004 | 1 | 0.240 |
Why?
|
| Lactams | 1 | 2004 | 4 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2013 | 235 | 0.240 |
Why?
|
| Schistosomiasis | 1 | 2004 | 6 | 0.240 |
Why?
|
| Urticaria | 2 | 2011 | 84 | 0.240 |
Why?
|
| Wasps | 1 | 2004 | 2 | 0.240 |
Why?
|
| Plummer-Vinson Syndrome | 1 | 2004 | 1 | 0.240 |
Why?
|
| 2-Aminopurine | 1 | 2004 | 5 | 0.240 |
Why?
|
| Kaposi Varicelliform Eruption | 1 | 2004 | 2 | 0.230 |
Why?
|
| Life Cycle Stages | 2 | 2018 | 7 | 0.230 |
Why?
|
| Disease Transmission, Infectious | 2 | 2018 | 25 | 0.230 |
Why?
|
| Foot Diseases | 2 | 2001 | 20 | 0.230 |
Why?
|
| Waardenburg Syndrome | 1 | 2004 | 5 | 0.230 |
Why?
|
| Acyclovir | 1 | 2004 | 38 | 0.230 |
Why?
|
| Valine | 1 | 2004 | 43 | 0.230 |
Why?
|
| Cohort Studies | 3 | 2015 | 2358 | 0.230 |
Why?
|
| Reference Values | 2 | 2016 | 579 | 0.230 |
Why?
|
| Dirofilaria | 1 | 2003 | 1 | 0.230 |
Why?
|
| Dirofilariasis | 1 | 2003 | 6 | 0.230 |
Why?
|
| Skin Care | 2 | 2020 | 14 | 0.230 |
Why?
|
| Infant | 4 | 2020 | 2891 | 0.230 |
Why?
|
| Thrombosis | 1 | 2005 | 218 | 0.230 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2003 | 2 | 0.230 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 2077 | 0.230 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2003 | 12 | 0.230 |
Why?
|
| Relief Work | 1 | 2003 | 13 | 0.220 |
Why?
|
| Exostoses | 1 | 2003 | 1 | 0.220 |
Why?
|
| Toes | 1 | 2003 | 27 | 0.220 |
Why?
|
| Enterobiasis | 1 | 2003 | 3 | 0.220 |
Why?
|
| Hepatitis B virus | 2 | 2020 | 23 | 0.220 |
Why?
|
| Graft vs Host Disease | 1 | 2005 | 163 | 0.220 |
Why?
|
| Mandibular Diseases | 1 | 2003 | 28 | 0.220 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 800 | 0.220 |
Why?
|
| Fatal Outcome | 3 | 2019 | 164 | 0.220 |
Why?
|
| Fever | 2 | 2019 | 96 | 0.220 |
Why?
|
| Strongyloides stercoralis | 1 | 2003 | 3 | 0.220 |
Why?
|
| Strongyloidiasis | 1 | 2003 | 5 | 0.220 |
Why?
|
| Abnormalities, Multiple | 1 | 2004 | 109 | 0.220 |
Why?
|
| Necrosis | 3 | 2013 | 239 | 0.220 |
Why?
|
| Irritants | 1 | 2023 | 10 | 0.220 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 125 | 0.220 |
Why?
|
| Deafness | 1 | 2004 | 64 | 0.220 |
Why?
|
| 4-Butyrolactone | 1 | 2022 | 1 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2004 | 514 | 0.210 |
Why?
|
| Tacrolimus | 1 | 2004 | 127 | 0.210 |
Why?
|
| Trichophyton | 1 | 2002 | 2 | 0.210 |
Why?
|
| Gout Suppressants | 1 | 2002 | 7 | 0.210 |
Why?
|
| Infant, Newborn | 5 | 2020 | 2455 | 0.210 |
Why?
|
| Drainage | 3 | 2008 | 133 | 0.210 |
Why?
|
| Lipoma | 2 | 2000 | 24 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 446 | 0.210 |
Why?
|
| Typhus, Endemic Flea-Borne | 3 | 2010 | 3 | 0.210 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2002 | 1 | 0.210 |
Why?
|
| Black Widow Spider | 1 | 2002 | 2 | 0.210 |
Why?
|
| Biological Therapy | 1 | 2022 | 8 | 0.210 |
Why?
|
| Glucocorticoids | 2 | 2020 | 222 | 0.210 |
Why?
|
| Plant Leaves | 1 | 2022 | 49 | 0.210 |
Why?
|
| Antiviral Agents | 2 | 2020 | 211 | 0.210 |
Why?
|
| Tuberous Sclerosis | 1 | 2002 | 13 | 0.200 |
Why?
|
| Tick Paralysis | 2 | 2018 | 2 | 0.200 |
Why?
|
| Pyrroles | 1 | 2022 | 83 | 0.200 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 148 | 0.200 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2022 | 25 | 0.200 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 567 | 0.200 |
Why?
|
| Holothurin | 1 | 2021 | 1 | 0.200 |
Why?
|
| Sea Cucumbers | 1 | 2021 | 1 | 0.200 |
Why?
|
| Keratinocytes | 2 | 2013 | 68 | 0.200 |
Why?
|
| Scleroderma, Systemic | 1 | 2005 | 446 | 0.200 |
Why?
|
| Fungi | 1 | 2001 | 27 | 0.200 |
Why?
|
| Models, Biological | 1 | 2006 | 981 | 0.200 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2018 | 79 | 0.190 |
Why?
|
| Seasons | 1 | 2022 | 129 | 0.190 |
Why?
|
| Keloid | 2 | 2016 | 10 | 0.190 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 25 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2022 | 107 | 0.190 |
Why?
|
| Calcineurin Inhibitors | 1 | 2021 | 24 | 0.190 |
Why?
|
| Phototherapy | 1 | 2021 | 28 | 0.190 |
Why?
|
| Ectodermal Dysplasia 1, Anhidrotic | 1 | 2021 | 2 | 0.190 |
Why?
|
| Nickel | 1 | 2001 | 18 | 0.190 |
Why?
|
| Australia | 1 | 2022 | 235 | 0.190 |
Why?
|
| Ectodermal Dysplasia | 1 | 2021 | 8 | 0.190 |
Why?
|
| Cellophane | 1 | 2000 | 1 | 0.190 |
Why?
|
| Pregnancy | 3 | 2013 | 2334 | 0.190 |
Why?
|
| Histological Techniques | 1 | 2000 | 10 | 0.190 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 9 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2010 | 504 | 0.190 |
Why?
|
| Biological Factors | 1 | 2020 | 11 | 0.180 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 20 | 0.180 |
Why?
|
| Virus Activation | 1 | 2020 | 15 | 0.180 |
Why?
|
| Foundations | 1 | 2020 | 17 | 0.180 |
Why?
|
| Nail-Patella Syndrome | 1 | 2000 | 1 | 0.180 |
Why?
|
| Addison Disease | 1 | 2000 | 2 | 0.180 |
Why?
|
| Leprostatic Agents | 1 | 2000 | 1 | 0.180 |
Why?
|
| Leprosy, Borderline | 1 | 2000 | 1 | 0.180 |
Why?
|
| Leprosy, Tuberculoid | 1 | 2000 | 1 | 0.180 |
Why?
|
| Databases, Factual | 2 | 2013 | 622 | 0.180 |
Why?
|
| Warts | 1 | 2000 | 6 | 0.180 |
Why?
|
| Baths | 1 | 2020 | 3 | 0.180 |
Why?
|
| Clothing | 1 | 2020 | 7 | 0.180 |
Why?
|
| Erythema Infectiosum | 1 | 2000 | 1 | 0.180 |
Why?
|
| Bacteriological Techniques | 1 | 2020 | 49 | 0.180 |
Why?
|
| Aminoquinolines | 1 | 2000 | 14 | 0.180 |
Why?
|
| Vasculitis | 2 | 2016 | 33 | 0.180 |
Why?
|
| Geography | 1 | 2020 | 80 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1745 | 0.180 |
Why?
|
| Melanoma, Amelanotic | 1 | 1999 | 1 | 0.180 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 186 | 0.180 |
Why?
|
| Whole Body Imaging | 1 | 2019 | 11 | 0.170 |
Why?
|
| Borrelia | 2 | 2017 | 2 | 0.170 |
Why?
|
| Adjuvants, Immunologic | 1 | 2000 | 63 | 0.170 |
Why?
|
| Sunscreening Agents | 1 | 2019 | 7 | 0.170 |
Why?
|
| Ehrlichia | 2 | 2017 | 6 | 0.170 |
Why?
|
| Iraq | 3 | 2004 | 24 | 0.170 |
Why?
|
| Sclerosis | 1 | 2019 | 32 | 0.170 |
Why?
|
| Herpesvirus 4, Human | 1 | 2019 | 30 | 0.170 |
Why?
|
| Neoplasms | 3 | 2018 | 1667 | 0.170 |
Why?
|
| Oral Ulcer | 1 | 2019 | 22 | 0.170 |
Why?
|
| Sex Distribution | 2 | 2015 | 274 | 0.170 |
Why?
|
| Anecdotes as Topic | 1 | 2019 | 4 | 0.170 |
Why?
|
| Osmolar Concentration | 1 | 2019 | 134 | 0.170 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 1999 | 3 | 0.170 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 86 | 0.170 |
Why?
|
| Age Distribution | 2 | 2015 | 320 | 0.170 |
Why?
|
| Adoptive Transfer | 2 | 2018 | 100 | 0.170 |
Why?
|
| Muir-Torre Syndrome | 1 | 2019 | 1 | 0.170 |
Why?
|
| Risk Management | 2 | 2009 | 37 | 0.170 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2019 | 7 | 0.170 |
Why?
|
| Hyperplasia | 2 | 2013 | 89 | 0.170 |
Why?
|
| Orbital Neoplasms | 1 | 1999 | 21 | 0.170 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 2279 | 0.170 |
Why?
|
| Cheek | 1 | 2019 | 11 | 0.170 |
Why?
|
| Eyelids | 1 | 2019 | 11 | 0.170 |
Why?
|
| Microscopy | 1 | 2019 | 64 | 0.170 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 157 | 0.170 |
Why?
|
| Outpatients | 1 | 2020 | 127 | 0.170 |
Why?
|
| Molluscum Contagiosum | 1 | 2019 | 3 | 0.160 |
Why?
|
| Delusional Parasitosis | 1 | 2018 | 2 | 0.160 |
Why?
|
| Estrogen Antagonists | 1 | 1998 | 10 | 0.160 |
Why?
|
| Elephantiasis | 1 | 1998 | 1 | 0.160 |
Why?
|
| Hyperostosis, Sternocostoclavicular | 1 | 1998 | 1 | 0.160 |
Why?
|
| Formularies as Topic | 1 | 1998 | 5 | 0.160 |
Why?
|
| Blepharitis | 2 | 2010 | 2 | 0.160 |
Why?
|
| Hospitals, Military | 1 | 1998 | 13 | 0.160 |
Why?
|
| Niacinamide | 1 | 1998 | 31 | 0.160 |
Why?
|
| Recurrence | 3 | 2017 | 948 | 0.160 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1998 | 62 | 0.160 |
Why?
|
| Tamoxifen | 1 | 1998 | 62 | 0.160 |
Why?
|
| Anaplasmosis | 1 | 2018 | 6 | 0.160 |
Why?
|
| Hemiptera | 1 | 1998 | 4 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2003 | 756 | 0.160 |
Why?
|
| Animals, Domestic | 2 | 2011 | 8 | 0.160 |
Why?
|
| Breast Diseases | 1 | 1998 | 40 | 0.160 |
Why?
|
| Pseudolymphoma | 1 | 2018 | 6 | 0.160 |
Why?
|
| Parasitic Diseases | 1 | 2018 | 9 | 0.160 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 1998 | 1 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1998 | 28 | 0.160 |
Why?
|
| Preoperative Period | 1 | 2018 | 50 | 0.160 |
Why?
|
| Coinfection | 1 | 2018 | 30 | 0.160 |
Why?
|
| Colorado Tick Fever | 1 | 2018 | 1 | 0.150 |
Why?
|
| Visual Perception | 1 | 2019 | 124 | 0.150 |
Why?
|
| Disease Outbreaks | 2 | 2009 | 83 | 0.150 |
Why?
|
| Rats | 2 | 2020 | 5300 | 0.150 |
Why?
|
| Mammaplasty | 1 | 1998 | 41 | 0.150 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 5 | 0.150 |
Why?
|
| Benzyl Alcohol | 1 | 2017 | 1 | 0.150 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 67 | 0.150 |
Why?
|
| Acute Disease | 2 | 2019 | 658 | 0.150 |
Why?
|
| Medical Overuse | 1 | 2018 | 28 | 0.150 |
Why?
|
| Child, Preschool | 5 | 2016 | 3187 | 0.150 |
Why?
|
| Search Engine | 1 | 2017 | 2 | 0.150 |
Why?
|
| Lower Extremity | 1 | 2019 | 153 | 0.150 |
Why?
|
| Databases, Bibliographic | 1 | 2017 | 14 | 0.150 |
Why?
|
| Sarcoma, Kaposi | 1 | 2018 | 25 | 0.150 |
Why?
|
| Planning Techniques | 1 | 2017 | 16 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 365 | 0.150 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 15 | 0.150 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 23 | 0.150 |
Why?
|
| Macrolides | 1 | 2017 | 48 | 0.150 |
Why?
|
| Blood-Borne Pathogens | 1 | 2017 | 7 | 0.150 |
Why?
|
| Dissection | 1 | 2018 | 29 | 0.150 |
Why?
|
| Sampling Studies | 1 | 2017 | 80 | 0.150 |
Why?
|
| Scientific Misconduct | 1 | 2017 | 12 | 0.150 |
Why?
|
| Needlestick Injuries | 1 | 2017 | 10 | 0.150 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.150 |
Why?
|
| Anticonvulsants | 1 | 1999 | 223 | 0.150 |
Why?
|
| Hexosaminidases | 1 | 2017 | 7 | 0.150 |
Why?
|
| Wound Healing | 1 | 2019 | 260 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2017 | 18 | 0.150 |
Why?
|
| Glucosyltransferases | 1 | 2017 | 28 | 0.150 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2017 | 17 | 0.150 |
Why?
|
| Chin | 1 | 2017 | 5 | 0.150 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2008 | 47 | 0.150 |
Why?
|
| Borrelia Infections | 1 | 2017 | 1 | 0.150 |
Why?
|
| Occupational Health | 1 | 2017 | 41 | 0.140 |
Why?
|
| Alkaline Ceramidase | 1 | 2017 | 35 | 0.140 |
Why?
|
| Drug Design | 1 | 2017 | 107 | 0.140 |
Why?
|
| Autoimmunity | 1 | 2018 | 118 | 0.140 |
Why?
|
| Patient Participation | 1 | 2018 | 146 | 0.140 |
Why?
|
| Lasers, Solid-State | 2 | 2016 | 8 | 0.140 |
Why?
|
| Research Personnel | 1 | 2017 | 83 | 0.140 |
Why?
|
| Global Health | 1 | 2017 | 136 | 0.140 |
Why?
|
| Health Personnel | 1 | 2020 | 286 | 0.140 |
Why?
|
| Glycosphingolipids | 1 | 2017 | 51 | 0.140 |
Why?
|
| Th17 Cells | 1 | 2018 | 116 | 0.140 |
Why?
|
| Hidrocystoma | 1 | 2016 | 1 | 0.140 |
Why?
|
| Sphingomyelins | 1 | 2017 | 106 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 65 | 0.140 |
Why?
|
| Dermabrasion | 1 | 2016 | 1 | 0.140 |
Why?
|
| Glycopyrrolate | 1 | 2016 | 3 | 0.140 |
Why?
|
| alpha-MSH | 1 | 2016 | 7 | 0.140 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2016 | 1 | 0.140 |
Why?
|
| Torso | 1 | 2016 | 3 | 0.140 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2017 | 93 | 0.140 |
Why?
|
| Face | 1 | 2017 | 46 | 0.140 |
Why?
|
| Colonoscopy | 1 | 2018 | 156 | 0.140 |
Why?
|
| Glucosylceramidase | 1 | 2017 | 50 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1996 | 41 | 0.140 |
Why?
|
| Genomics | 1 | 2018 | 168 | 0.140 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2017 | 62 | 0.140 |
Why?
|
| Neck | 1 | 2017 | 62 | 0.140 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2016 | 3 | 0.140 |
Why?
|
| Developing Countries | 1 | 2017 | 106 | 0.140 |
Why?
|
| Cell Nucleolus | 1 | 2016 | 14 | 0.140 |
Why?
|
| Isotretinoin | 1 | 2016 | 8 | 0.140 |
Why?
|
| Eyelid Neoplasms | 1 | 2016 | 12 | 0.140 |
Why?
|
| Registries | 1 | 2020 | 733 | 0.140 |
Why?
|
| Occupational Exposure | 1 | 2017 | 122 | 0.140 |
Why?
|
| Hepatitis C, Chronic | 1 | 1998 | 86 | 0.140 |
Why?
|
| Radiation Exposure | 1 | 2018 | 84 | 0.140 |
Why?
|
| Cell Death | 1 | 2017 | 329 | 0.140 |
Why?
|
| Oxyphil Cells | 1 | 2016 | 1 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 199 | 0.140 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2016 | 1 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2016 | 86 | 0.140 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 247 | 0.140 |
Why?
|
| Specimen Handling | 2 | 2016 | 47 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 87 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 468 | 0.140 |
Why?
|
| Choice Behavior | 1 | 2017 | 85 | 0.140 |
Why?
|
| Muscarinic Antagonists | 1 | 2016 | 54 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 61 | 0.130 |
Why?
|
| Panniculitis | 1 | 2016 | 7 | 0.130 |
Why?
|
| Chromatin | 1 | 2016 | 76 | 0.130 |
Why?
|
| Blood Coagulation Factors | 2 | 2007 | 44 | 0.130 |
Why?
|
| User-Computer Interface | 1 | 2017 | 230 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 694 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 194 | 0.130 |
Why?
|
| Argyria | 1 | 2015 | 1 | 0.130 |
Why?
|
| Immunoglobulin A | 1 | 2016 | 79 | 0.130 |
Why?
|
| Chloracne | 1 | 2015 | 1 | 0.130 |
Why?
|
| Complement C3 | 1 | 2016 | 101 | 0.130 |
Why?
|
| Lysophospholipids | 1 | 2017 | 209 | 0.130 |
Why?
|
| Smooth Muscle Tumor | 1 | 2015 | 1 | 0.130 |
Why?
|
| Cellulitis | 2 | 2013 | 13 | 0.130 |
Why?
|
| Agent Orange | 1 | 2015 | 1 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1996 | 138 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 214 | 0.130 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 33 | 0.130 |
Why?
|
| Vietnam | 1 | 2015 | 36 | 0.130 |
Why?
|
| Muscle Neoplasms | 1 | 2015 | 9 | 0.130 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2017 | 201 | 0.130 |
Why?
|
| Arm | 1 | 2015 | 59 | 0.130 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2017 | 183 | 0.130 |
Why?
|
| Silicon Dioxide | 1 | 2015 | 61 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 1999 | 371 | 0.130 |
Why?
|
| Age Factors | 2 | 2013 | 1864 | 0.130 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 53 | 0.130 |
Why?
|
| Sphingosine | 1 | 2017 | 315 | 0.130 |
Why?
|
| Safety | 1 | 2015 | 145 | 0.130 |
Why?
|
| Smoke | 1 | 2015 | 46 | 0.120 |
Why?
|
| Monophenol Monooxygenase | 1 | 2014 | 8 | 0.120 |
Why?
|
| Light | 1 | 2015 | 152 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 261 | 0.120 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 131 | 0.120 |
Why?
|
| 12E7 Antigen | 1 | 2014 | 2 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 955 | 0.120 |
Why?
|
| Antioxidants | 1 | 2016 | 304 | 0.120 |
Why?
|
| Catheter Ablation | 1 | 2016 | 229 | 0.120 |
Why?
|
| Erythromycin | 1 | 2014 | 13 | 0.120 |
Why?
|
| Office Visits | 2 | 2017 | 83 | 0.120 |
Why?
|
| Anaphylaxis | 2 | 2004 | 43 | 0.120 |
Why?
|
| Temperature | 1 | 2015 | 341 | 0.120 |
Why?
|
| Antigens, Neoplasm | 2 | 2005 | 132 | 0.110 |
Why?
|
| Common Variable Immunodeficiency | 1 | 1993 | 7 | 0.110 |
Why?
|
| Histiocytes | 1 | 1993 | 8 | 0.110 |
Why?
|
| Candidiasis, Cutaneous | 1 | 2013 | 1 | 0.110 |
Why?
|
| Tattooing | 1 | 1993 | 6 | 0.110 |
Why?
|
| Aluminum | 1 | 1993 | 21 | 0.110 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 481 | 0.110 |
Why?
|
| Venous Valves | 1 | 2013 | 1 | 0.110 |
Why?
|
| Epithelium | 1 | 2013 | 172 | 0.110 |
Why?
|
| Birefringence | 1 | 2013 | 1 | 0.110 |
Why?
|
| Quality of Life | 1 | 2022 | 1515 | 0.110 |
Why?
|
| Azure Stains | 1 | 2013 | 4 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2016 | 384 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.110 |
Why?
|
| Epidermal Cyst | 1 | 1993 | 3 | 0.110 |
Why?
|
| Autopsy | 1 | 2013 | 56 | 0.110 |
Why?
|
| Ceramides | 1 | 2017 | 578 | 0.110 |
Why?
|
| Neurodermatitis | 1 | 2013 | 1 | 0.110 |
Why?
|
| DNA, Bacterial | 2 | 2007 | 150 | 0.110 |
Why?
|
| Glycogen | 1 | 2013 | 27 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1553 | 0.110 |
Why?
|
| Tumor Virus Infections | 1 | 1993 | 32 | 0.110 |
Why?
|
| Aging | 1 | 2019 | 911 | 0.110 |
Why?
|
| Prednisone | 2 | 2003 | 104 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2013 | 242 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2017 | 617 | 0.110 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2012 | 24 | 0.100 |
Why?
|
| Tobacco Products | 1 | 2015 | 234 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 219 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 330 | 0.100 |
Why?
|
| Trichotillomania | 1 | 2012 | 14 | 0.100 |
Why?
|
| Hand | 2 | 2003 | 90 | 0.100 |
Why?
|
| Gnathostoma | 1 | 2011 | 1 | 0.100 |
Why?
|
| Gnathostomiasis | 1 | 2011 | 1 | 0.100 |
Why?
|
| Seafood | 1 | 2011 | 17 | 0.100 |
Why?
|
| Career Mobility | 1 | 2012 | 34 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 689 | 0.100 |
Why?
|
| Food Contamination | 1 | 2011 | 56 | 0.100 |
Why?
|
| Granuloma Annulare | 1 | 2011 | 4 | 0.100 |
Why?
|
| Herpes Simplex | 1 | 2011 | 35 | 0.100 |
Why?
|
| Mentors | 1 | 2012 | 81 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 454 | 0.100 |
Why?
|
| Melanins | 1 | 2011 | 24 | 0.100 |
Why?
|
| Spasm | 1 | 2011 | 18 | 0.090 |
Why?
|
| Abscess | 2 | 2008 | 37 | 0.090 |
Why?
|
| Endophthalmitis | 1 | 2011 | 15 | 0.090 |
Why?
|
| Receptors, Transferrin | 1 | 2010 | 18 | 0.090 |
Why?
|
| Acaricides | 1 | 2010 | 2 | 0.090 |
Why?
|
| Fruit | 1 | 2011 | 86 | 0.090 |
Why?
|
| South America | 1 | 2010 | 8 | 0.090 |
Why?
|
| Bartonella henselae | 1 | 2010 | 9 | 0.090 |
Why?
|
| Fusarium | 1 | 2010 | 5 | 0.090 |
Why?
|
| Leukemic Infiltration | 1 | 2010 | 2 | 0.090 |
Why?
|
| Myxedema | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cat-Scratch Disease | 1 | 2010 | 10 | 0.090 |
Why?
|
| Voriconazole | 1 | 2010 | 11 | 0.090 |
Why?
|
| Mucins | 1 | 2010 | 22 | 0.090 |
Why?
|
| Balanitis | 1 | 2010 | 1 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2010 | 120 | 0.090 |
Why?
|
| Skin Diseases, Viral | 1 | 2010 | 2 | 0.090 |
Why?
|
| Radiography | 2 | 2004 | 572 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 1266 | 0.090 |
Why?
|
| Doxycycline | 1 | 2010 | 49 | 0.090 |
Why?
|
| Thyroid Diseases | 1 | 2010 | 33 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 44 | 0.090 |
Why?
|
| History, Ancient | 1 | 2009 | 25 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2012 | 383 | 0.080 |
Why?
|
| Malpractice | 1 | 2009 | 15 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 240 | 0.080 |
Why?
|
| Organizational Culture | 1 | 2009 | 59 | 0.080 |
Why?
|
| Biomarkers | 1 | 2014 | 1593 | 0.080 |
Why?
|
| Clarithromycin | 1 | 2009 | 11 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 47 | 0.080 |
Why?
|
| Brazil | 1 | 2009 | 48 | 0.080 |
Why?
|
| Angiography | 1 | 2010 | 194 | 0.080 |
Why?
|
| Patch Tests | 1 | 2008 | 5 | 0.080 |
Why?
|
| Ink | 1 | 2008 | 8 | 0.080 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2009 | 22 | 0.080 |
Why?
|
| Hand Disinfection | 1 | 2008 | 9 | 0.080 |
Why?
|
| Canada | 1 | 2009 | 267 | 0.080 |
Why?
|
| Microscopy, Electron | 3 | 1993 | 351 | 0.080 |
Why?
|
| Hyperthyroidism | 1 | 2008 | 13 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2007 | 186 | 0.080 |
Why?
|
| Mice | 1 | 2020 | 8474 | 0.080 |
Why?
|
| Fomites | 1 | 2008 | 12 | 0.080 |
Why?
|
| Blood Protein Electrophoresis | 1 | 2007 | 7 | 0.080 |
Why?
|
| Debridement | 1 | 2008 | 55 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 2324 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 123 | 0.080 |
Why?
|
| Equipment Contamination | 1 | 2008 | 38 | 0.080 |
Why?
|
| Remission, Spontaneous | 2 | 1997 | 25 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2017 | 2689 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2007 | 43 | 0.070 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2007 | 19 | 0.070 |
Why?
|
| Receptors, Progesterone | 1 | 2007 | 57 | 0.070 |
Why?
|
| Genes, BRCA2 | 1 | 2007 | 35 | 0.070 |
Why?
|
| Genes, BRCA1 | 1 | 2007 | 47 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2010 | 346 | 0.070 |
Why?
|
| Africa | 1 | 2007 | 41 | 0.070 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 2007 | 1 | 0.070 |
Why?
|
| Injections, Intradermal | 1 | 2007 | 6 | 0.070 |
Why?
|
| Cephalexin | 1 | 2006 | 1 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2006 | 274 | 0.070 |
Why?
|
| Classification | 1 | 2006 | 8 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2007 | 35 | 0.070 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2006 | 13 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2007 | 142 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2007 | 95 | 0.070 |
Why?
|
| Partial Thromboplastin Time | 1 | 2007 | 57 | 0.070 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2007 | 18 | 0.070 |
Why?
|
| Population Dynamics | 1 | 2006 | 30 | 0.070 |
Why?
|
| Virulence | 1 | 2007 | 51 | 0.070 |
Why?
|
| Platelet Count | 1 | 2007 | 100 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2007 | 129 | 0.070 |
Why?
|
| Silver Nitrate | 1 | 2006 | 6 | 0.070 |
Why?
|
| Cephalosporins | 1 | 2006 | 59 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2006 | 95 | 0.070 |
Why?
|
| Bardet-Biedl Syndrome | 1 | 2006 | 2 | 0.070 |
Why?
|
| Dandy-Walker Syndrome | 1 | 2006 | 3 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2007 | 85 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2007 | 141 | 0.070 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2006 | 4 | 0.070 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2006 | 4 | 0.070 |
Why?
|
| Sulfacetamide | 1 | 2005 | 1 | 0.070 |
Why?
|
| Hair Preparations | 1 | 2005 | 2 | 0.070 |
Why?
|
| Rickettsiaceae Infections | 1 | 2005 | 3 | 0.070 |
Why?
|
| Lymph | 1 | 2005 | 8 | 0.070 |
Why?
|
| HLA-A2 Antigen | 1 | 2005 | 18 | 0.070 |
Why?
|
| Sodium Channels | 1 | 2005 | 24 | 0.070 |
Why?
|
| Sclerotherapy | 1 | 2005 | 10 | 0.070 |
Why?
|
| South Africa | 1 | 2005 | 45 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2008 | 287 | 0.070 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2005 | 14 | 0.070 |
Why?
|
| Selenium Compounds | 1 | 2005 | 14 | 0.070 |
Why?
|
| Sulfur | 1 | 2005 | 16 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 55 | 0.060 |
Why?
|
| Neurofibromatosis 1 | 1 | 2006 | 39 | 0.060 |
Why?
|
| Calcium Channels | 1 | 2005 | 59 | 0.060 |
Why?
|
| Marine Toxins | 1 | 2005 | 14 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 207 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2005 | 78 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2005 | 122 | 0.060 |
Why?
|
| Retinoids | 1 | 2006 | 122 | 0.060 |
Why?
|
| DEET | 1 | 2004 | 5 | 0.060 |
Why?
|
| Fibrinogen | 1 | 2005 | 87 | 0.060 |
Why?
|
| HIV Infections | 2 | 2017 | 791 | 0.060 |
Why?
|
| Mosquito Control | 1 | 2004 | 4 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2005 | 248 | 0.060 |
Why?
|
| Skin Tests | 1 | 2004 | 30 | 0.060 |
Why?
|
| Onchocerciasis | 1 | 2004 | 4 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 951 | 0.060 |
Why?
|
| Ovum | 1 | 2004 | 24 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 2005 | 383 | 0.060 |
Why?
|
| Travel | 1 | 2004 | 38 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 2004 | 53 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2003 | 13 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 786 | 0.060 |
Why?
|
| Nails, Malformed | 1 | 2003 | 2 | 0.060 |
Why?
|
| Tinea Capitis | 1 | 2003 | 2 | 0.060 |
Why?
|
| Giant Cells | 1 | 2003 | 14 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2003 | 23 | 0.060 |
Why?
|
| Macrophages | 2 | 2000 | 647 | 0.060 |
Why?
|
| North America | 1 | 2003 | 112 | 0.060 |
Why?
|
| Rheumatic Diseases | 1 | 2003 | 35 | 0.060 |
Why?
|
| Pseudomonas Infections | 1 | 2004 | 83 | 0.060 |
Why?
|
| Malaria | 1 | 2003 | 26 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2003 | 47 | 0.060 |
Why?
|
| Diptera | 2 | 2004 | 9 | 0.060 |
Why?
|
| Mucormycosis | 1 | 2003 | 6 | 0.060 |
Why?
|
| Aspergillosis | 1 | 2003 | 20 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 144 | 0.050 |
Why?
|
| Mouth | 1 | 2003 | 64 | 0.050 |
Why?
|
| Perylene | 1 | 2022 | 4 | 0.050 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2002 | 3 | 0.050 |
Why?
|
| Anthracenes | 1 | 2022 | 26 | 0.050 |
Why?
|
| Back | 1 | 2002 | 6 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2003 | 45 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2022 | 32 | 0.050 |
Why?
|
| Internet | 1 | 2005 | 390 | 0.050 |
Why?
|
| Comorbidity | 1 | 2007 | 1426 | 0.050 |
Why?
|
| Granulocytes | 1 | 2002 | 22 | 0.050 |
Why?
|
| Isoantigens | 1 | 2002 | 26 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2005 | 442 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 2002 | 68 | 0.050 |
Why?
|
| Neutrophils | 2 | 2000 | 204 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2003 | 649 | 0.050 |
Why?
|
| Tinea Pedis | 1 | 2001 | 2 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2003 | 109 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2002 | 216 | 0.050 |
Why?
|
| Cefadroxil | 1 | 2021 | 1 | 0.050 |
Why?
|
| Mupirocin | 1 | 2021 | 1 | 0.050 |
Why?
|
| Public Health | 1 | 2003 | 201 | 0.050 |
Why?
|
| Eyeglasses | 1 | 2001 | 11 | 0.050 |
Why?
|
| Infection Control | 1 | 2002 | 101 | 0.050 |
Why?
|
| Ectodysplasins | 1 | 2021 | 7 | 0.050 |
Why?
|
| Antipruritics | 1 | 2000 | 3 | 0.050 |
Why?
|
| Tissue Engineering | 1 | 2003 | 212 | 0.050 |
Why?
|
| Penicillamine | 1 | 2000 | 10 | 0.050 |
Why?
|
| Azathioprine | 1 | 2000 | 16 | 0.050 |
Why?
|
| Nifedipine | 1 | 2000 | 40 | 0.050 |
Why?
|
| Pedigree | 1 | 2021 | 159 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 159 | 0.050 |
Why?
|
| DNA | 1 | 2003 | 597 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 597 | 0.050 |
Why?
|
| Hair Color | 1 | 2000 | 4 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2000 | 51 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2000 | 62 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2000 | 59 | 0.050 |
Why?
|
| Clofazimine | 1 | 2000 | 1 | 0.050 |
Why?
|
| Colloids | 1 | 2000 | 43 | 0.050 |
Why?
|
| Chromosome Disorders | 1 | 2000 | 31 | 0.040 |
Why?
|
| Arthritis | 1 | 2000 | 53 | 0.040 |
Why?
|
| Exophiala | 1 | 2000 | 4 | 0.040 |
Why?
|
| Fungemia | 1 | 2000 | 13 | 0.040 |
Why?
|
| Minocycline | 1 | 2000 | 61 | 0.040 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2000 | 12 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2000 | 51 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2000 | 138 | 0.040 |
Why?
|
| Steroids | 1 | 2000 | 84 | 0.040 |
Why?
|
| Technology, Pharmaceutical | 1 | 2019 | 8 | 0.040 |
Why?
|
| Phthiraptera | 1 | 1999 | 1 | 0.040 |
Why?
|
| Rifampin | 1 | 2000 | 45 | 0.040 |
Why?
|
| Algorithms | 1 | 2005 | 1196 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2000 | 202 | 0.040 |
Why?
|
| Carbaryl | 1 | 1999 | 1 | 0.040 |
Why?
|
| Piperonyl Butoxide | 1 | 1999 | 8 | 0.040 |
Why?
|
| Petrolatum | 1 | 1999 | 3 | 0.040 |
Why?
|
| Trimethoprim | 1 | 1999 | 8 | 0.040 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1999 | 22 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2550 | 0.040 |
Why?
|
| Mosaicism | 1 | 1999 | 21 | 0.040 |
Why?
|
| Triazines | 1 | 1999 | 48 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2000 | 121 | 0.040 |
Why?
|
| Thigh | 1 | 2019 | 27 | 0.040 |
Why?
|
| Hypertension | 1 | 2008 | 1535 | 0.040 |
Why?
|
| Valproic Acid | 1 | 1999 | 93 | 0.040 |
Why?
|
| Phlebotomus | 1 | 1998 | 1 | 0.040 |
Why?
|
| Drug Interactions | 1 | 1999 | 289 | 0.040 |
Why?
|
| Cat Diseases | 1 | 1998 | 7 | 0.040 |
Why?
|
| CD30 Ligand | 1 | 2018 | 1 | 0.040 |
Why?
|
| Tooth, Impacted | 1 | 1998 | 3 | 0.040 |
Why?
|
| Jaw Diseases | 1 | 1998 | 7 | 0.040 |
Why?
|
| Odontogenic Cysts | 1 | 1998 | 13 | 0.040 |
Why?
|
| Exotropia | 1 | 1998 | 9 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1342 | 0.040 |
Why?
|
| Molar | 1 | 1998 | 27 | 0.040 |
Why?
|
| Axilla | 1 | 2018 | 36 | 0.040 |
Why?
|
| Transfusion Reaction | 1 | 1998 | 33 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 51 | 0.040 |
Why?
|
| Orbit | 1 | 1998 | 30 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2000 | 284 | 0.040 |
Why?
|
| Cell Movement | 1 | 2000 | 630 | 0.040 |
Why?
|
| Maxilla | 1 | 1998 | 63 | 0.040 |
Why?
|
| Agriculture | 1 | 1997 | 54 | 0.040 |
Why?
|
| Capillaries | 2 | 2013 | 105 | 0.040 |
Why?
|
| Skin Diseases, Vascular | 1 | 1996 | 3 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2017 | 90 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 127 | 0.040 |
Why?
|
| Embolism | 1 | 1996 | 45 | 0.040 |
Why?
|
| Teratogens | 1 | 2016 | 11 | 0.030 |
Why?
|
| Endocarditis, Bacterial | 1 | 1996 | 32 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 1998 | 249 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 111 | 0.030 |
Why?
|
| Metaplasia | 1 | 2016 | 27 | 0.030 |
Why?
|
| Genitalia, Female | 1 | 2016 | 20 | 0.030 |
Why?
|
| Anal Canal | 1 | 2016 | 28 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2017 | 114 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 59 | 0.030 |
Why?
|
| Nose | 1 | 2015 | 36 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 1213 | 0.030 |
Why?
|
| Bandages | 1 | 2015 | 33 | 0.030 |
Why?
|
| Epilepsy | 1 | 1999 | 336 | 0.030 |
Why?
|
| Suicide | 1 | 2016 | 116 | 0.030 |
Why?
|
| Rickettsia rickettsii | 1 | 2014 | 1 | 0.030 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2014 | 3 | 0.030 |
Why?
|
| Francisella tularensis | 1 | 2014 | 2 | 0.030 |
Why?
|
| Q Fever | 1 | 2014 | 2 | 0.030 |
Why?
|
| Coxiella burnetii | 1 | 2014 | 2 | 0.030 |
Why?
|
| Nevus, Blue | 1 | 1993 | 3 | 0.030 |
Why?
|
| Prednisolone | 1 | 1993 | 23 | 0.030 |
Why?
|
| Electron Probe Microanalysis | 1 | 1993 | 16 | 0.030 |
Why?
|
| Cautery | 1 | 1993 | 5 | 0.030 |
Why?
|
| Aluminum Compounds | 1 | 1993 | 10 | 0.030 |
Why?
|
| Hidradenitis | 1 | 1993 | 2 | 0.030 |
Why?
|
| Chlorides | 1 | 1993 | 68 | 0.030 |
Why?
|
| Hamartoma | 1 | 1993 | 24 | 0.030 |
Why?
|
| Phosphorus | 1 | 1993 | 64 | 0.030 |
Why?
|
| Keratins | 1 | 1993 | 48 | 0.030 |
Why?
|
| Vimentin | 1 | 1993 | 47 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 1993 | 62 | 0.030 |
Why?
|
| Forearm | 1 | 1993 | 25 | 0.030 |
Why?
|
| Color | 1 | 2013 | 50 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 135 | 0.030 |
Why?
|
| Edema | 1 | 2013 | 66 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2013 | 168 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1993 | 116 | 0.030 |
Why?
|
| Albendazole | 1 | 2011 | 1 | 0.030 |
Why?
|
| Cell Count | 1 | 2012 | 248 | 0.030 |
Why?
|
| Antinematodal Agents | 1 | 2011 | 4 | 0.030 |
Why?
|
| Subcutaneous Tissue | 1 | 2011 | 6 | 0.020 |
Why?
|
| Leukosialin | 1 | 2010 | 2 | 0.020 |
Why?
|
| CD5 Antigens | 1 | 2010 | 5 | 0.020 |
Why?
|
| Antigens, CD20 | 1 | 2010 | 6 | 0.020 |
Why?
|
| Receptors, IgE | 1 | 2010 | 22 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2010 | 35 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1054 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1038 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2800 | 0.020 |
Why?
|
| Calcium | 1 | 1993 | 929 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 943 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 329 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 2006 | 12 | 0.020 |
Why?
|
| Wound Infection | 1 | 2006 | 20 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 226 | 0.020 |
Why?
|
| Self Medication | 1 | 2005 | 25 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3705 | 0.020 |
Why?
|
| Filaricides | 1 | 2004 | 1 | 0.010 |
Why?
|
| Disease Reservoirs | 1 | 2004 | 7 | 0.010 |
Why?
|
| Onchocerca volvulus | 1 | 2004 | 3 | 0.010 |
Why?
|
| Rhizopus | 1 | 2003 | 1 | 0.010 |
Why?
|
| Aspergillus | 1 | 2003 | 8 | 0.010 |
Why?
|
| Acitretin | 1 | 2002 | 1 | 0.010 |
Why?
|
| Keratolytic Agents | 1 | 2002 | 4 | 0.010 |
Why?
|
| Frozen Sections | 1 | 2002 | 14 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 242 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2001 | 58 | 0.010 |
Why?
|
| Tick Control | 1 | 2000 | 1 | 0.010 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 1999 | 4 | 0.010 |
Why?
|
| Abdomen | 1 | 1998 | 80 | 0.010 |
Why?
|
| Neural Crest | 1 | 1993 | 58 | 0.010 |
Why?
|